SHILPA MEDICARE LTD

398.25 +0.65 (+0.16%) Buy

Are you evaluating investing in SHILPAMED? Consider as it managed to marginally outperform the broader market

15 min read

SHILPA MEDICARE LTD managed to marginally outperform the broader market on Friday. It gained +0.16% to close at 398.25. It is currently trading -34% below it's 52 week high of 605.7.

[Themes containing SHILPAMED]

SHILPAMED showed a up trend over the last 3 months. During this period SHILPAMED gained +1.07% and saw a maximum drawdown of -8.23%. There was a long signal during this period which returned +3.48%.

Trend

SHILPAMED has been outperforming the NIFTY-50 index in recent time. Over the last 3 years and 1 month, SHILPAMED underperformed the NIFTY-50 index on 55% days.

SHILPAMED returned losses on 53% days in the last three months. During this time, it delivered on average +0.03% per day. It delivered it's best daily return of +4.09%, during this period, on Friday, 16 Nov, 2018. There was initially a bullish trend during this period which started on 25 Oct, 2018 and went on till 29 Oct, 2018. The bullish trend returned +2.8% to investors. This was followed by a bearish trend that started on 9 Nov, 2018 and ended on 15 Nov, 2018. This bearish trend lost -7.92% of investor capital.

SHILPAMED had 7 profitable and 5 loss making months over the last year. SHILPAMED was profitable in more months than NIFTY-50 index. SHILPAMED significantly outperformed NIFTY-50 index in Aug 2018, when it returned +23.81% compared to +6.56% returned by NIFTY-50 index during it's best month in the last one year - Jul 2018. SHILPAMED had a longer winning streak of profitable months than NIFTY-50 index. It went up in 3 straight months (from Jun 2018 to Aug 2018) during which period it delivered +29.64%. It is interesting to note that both SHILPAMED and NIFTY-50 index significantly outperform during months when quarterly/annual results are announced.

"The underlying principles of sound investment should not alter from decade to decade, but the application of these principles must be adapted to significant changes in the financial mechanisms and climate.

SHILPAMED is becoming more volatile overall. In comparison, the NIFTY-50 index is seeing a fall in volatility. During the last three months, there was a significant fall in SHILPAMED's volatility from 16 Nov, 2018 to 17 Dec, 2018. While there was a significant fall in the NIFTY-50 index's volatility from 31 Oct, 2018 to 5 Dec, 2018.

Advanced/professional short-term investors should note that SHILPAMED has significant negative skewness in it's return distribution. This indicates that SHILPAMED is very risky for short-term investment and can significantly underperform for long durations.

NIFTY-50 index has more chance of extreme outcomes than SHILPAMED. Therefore, NIFTY-50 must receive a lower allocation than SHILPAMED in your portfolio. NIFTY-50 index usually has shorter drawdown period than SHILPAMED.

On a general note (since you are interested in SHILPAMED), two instruments that have delivered similar performance as SHILPAMED are WENDT and POLYMED. They are suitable as good alternative investment candidates that can diversify your portfolio.

Want to improve your Portfolio's performance?

Spotalpha's Portfolio optimizer is all you need to improve your returns and reduce your risk.
Optimize Portfolio NOW
If you liked what you read here ...

... we have a small favour to ask. Help us bring the power of algorithmic trading strategies to individual investors.

All content in this article was automatically generated by algorithms. This ensures that there are no human biases in the analysis provided. This approach to investing is not new and has been around for more than three decades. Yet, it has been available to only the most affluent or elite investors leaving individual investors to trade on emotions (such as fear and greed), intuition and poor analysis from third-parties. We want to change this.

We want to empower investors with all the tools and analysis required by them to make a rational investment decision.

If you found Spotalpha useful, consider making a contribution. For as little as $5 you can support our efforts and it takes less than a minute. Thank you. Contribute
Share with friends   WhatsApp   Facebook   Twitter